Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma

Craig S. Sauter; Matthew J. Matasar; Jessica Meikle; Heiko Schoder; Gary A. Ulaner; Jocelyn C. Migliacci; Patrick Hilden; Sean M. Devlin; Andrew D. Zelenetz; Craig H. Moskowitz

doi:10.1182/blood-2014-10-606939

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma

Craig S. Sauter, Matthew J. Matasar, Jessica Meikle, Heiko Schoder, Gary A. Ulaner, Jocelyn C. Migliacci, Patrick Hilden, Sean M. Devlin, Andrew D. Zelenetz, Craig H. Moskowitz

Research output: Contribution to journal › Article › peer-review

70 Scopus citations

Abstract

High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using ¹⁸F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.

Original language	English (US)
Pages (from-to)	2579-2581
Number of pages	3
Journal	Blood
Volume	125
Issue number	16
DOIs	https://doi.org/10.1182/blood-2014-10-606939
State	Published - Apr 16 2015
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2014-10-606939

Cite this

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. / Sauter, Craig S.; Matasar, Matthew J.; Meikle, Jessica; Schoder, Heiko; Ulaner, Gary A.; Migliacci, Jocelyn C.; Hilden, Patrick; Devlin, Sean M.; Zelenetz, Andrew D.; Moskowitz, Craig H.

In: Blood, Vol. 125, No. 16, 16.04.2015, p. 2579-2581.

Research output: Contribution to journal › Article › peer-review

Sauter, Craig S. ; Matasar, Matthew J. ; Meikle, Jessica ; Schoder, Heiko ; Ulaner, Gary A. ; Migliacci, Jocelyn C. ; Hilden, Patrick ; Devlin, Sean M. ; Zelenetz, Andrew D. ; Moskowitz, Craig H. / Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. In: Blood. 2015 ; Vol. 125, No. 16. pp. 2579-2581.

@article{ef5fbac988b846e2a62614a02241550c,

title = "Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma",

abstract = "High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.",

author = "Sauter, {Craig S.} and Matasar, {Matthew J.} and Jessica Meikle and Heiko Schoder and Ulaner, {Gary A.} and Migliacci, {Jocelyn C.} and Patrick Hilden and Devlin, {Sean M.} and Zelenetz, {Andrew D.} and Moskowitz, {Craig H.}",

note = "Publisher Copyright: {\textcopyright} 2015 by The American Society of Hematology.",

year = "2015",

month = apr,

day = "16",

doi = "10.1182/blood-2014-10-606939",

language = "English (US)",

volume = "125",

pages = "2579--2581",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "16",

}

TY - JOUR

T1 - Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma

AU - Sauter, Craig S.

AU - Matasar, Matthew J.

AU - Meikle, Jessica

AU - Schoder, Heiko

AU - Ulaner, Gary A.

AU - Migliacci, Jocelyn C.

AU - Hilden, Patrick

AU - Devlin, Sean M.

AU - Zelenetz, Andrew D.

AU - Moskowitz, Craig H.

PY - 2015/4/16

Y1 - 2015/4/16

N2 - High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.

AB - High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.

UR - http://www.scopus.com/inward/record.url?scp=84927751342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927751342&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-10-606939

DO - 10.1182/blood-2014-10-606939

M3 - Article

C2 - 25758829

AN - SCOPUS:84927751342

VL - 125

SP - 2579

EP - 2581

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this